Image

Success Rates of Expectant vs. Medical Management for Retained Products After First-Trimester Abortion: Randomized Controlled Trial

Success Rates of Expectant vs. Medical Management for Retained Products After First-Trimester Abortion: Randomized Controlled Trial

Recruiting
18-45 years
Female
Phase N/A

Powered by AI

Overview

This prospective randomized controlled trial evaluates the success of medical versus expectant management for retained products of conception (RPOC) following medical abortion with mifepristone and misoprostol for delayed miscarriage in the first trimester. Women aged 18-45 with sonographic evidence of RPOC (endometrial thickness \>10 mm with Doppler flow) will be randomized into two groups: medical management with misoprostol or expectant management (observation only). Follow-up will include ultrasound evaluations over six weeks to monitor uterine clearance and determine further interventions.

Population: 150 participants, with 75 in each group. Inclusion Criteria: Stable women with RPOC after medical abortion, bleeding comparable to menstrual flow, and no fever.

Exclusion Criteria: Hemodynamic instability, excessive bleeding, fever, or specific endometrial thickness criteria.

Outcome Measures: RPOC resolution, need for surgical intervention, complications, and sonographic changes.

Study Duration: Five years. Data on demographics, medical history, and ultrasound findings will be analyzed using SPSS, with results informing optimal management strategies for RPOC after first-trimester medical abortion.

Description

Study Goals:

  • Primary Objectives: Evaluate the effectiveness of medical management with misoprostol and expectant management for retained products of conception (RPOC) following medical abortion for delayed miscarriage in the first trimester (up to 12 weeks).
  • Secondary Objectives: Assess the safety and complications of expectant versus medical management of RPOC.

Study Design:

  • Prospective study involving women diagnosed with RPOC following medical abortion with mifepristone and misoprostol for delayed miscarriage in the first trimester.
  • Participants will be randomized into two groups: medical management with misoprostol and expectant management (observation only).
  • Data will be collected through three follow-up visits over six weeks, with ultrasound evaluations to monitor uterine content and decide on further interventions, if necessary.
    Population

Women aged 18-45 diagnosed with delayed miscarriage up to 12 weeks gestation, with sonographic evidence of RPOC after medical abortion using mifepristone and misoprostol.

Inclusion Criteria:

  1. Age 18-45.
  2. RPOC identified on ultrasound after medical abortion, defined as endometrial thickness \>10 mm with Doppler flow into the uterine cavity.
  3. Hemodynamically stable women with bleeding comparable to menstrual flow, without fever.

Exclusion Criteria:

  1. Hemodynamic instability, excessive bleeding, or fever.
  2. Endometrial thickness \>40 mm.
  3. Endometrial thickness \<10 mm without Doppler flow into the cavity.
  4. Presence of a gestational sac within the uterine cavity.
  5. Women who received two doses of misoprostol before evaluation. Study Duration:Five years.

Sample Size:

Based on previous studies, 124 women (62 per group) are required for 80% power at a 5% significance level. Accounting for potential attrition, a total of 150 participants will be recruited (75 in each group).

Data Collection:

  • Demographic data (age, ethnicity, weight, height).
  • Medical history (chronic conditions, medications).
  • Obstetric and gynecologic history.
  • Current pregnancy details (gestational age, method of conception).
  • Sonographic data at diagnosis and follow-ups (endometrial thickness, RPOC dimensions, Doppler flow parameters).
  • Complications during the process (surgical interventions, blood transfusions, infections, intrauterine adhesions).

Statistical Analysis:

Data will be analyzed using SPSS software. ANOVA will assess differences between groups on outcomes.

Confidentiality

All data will be anonymized and stored securely, with access limited to the primary and co-investigators. Data will be retained for 15 years.

Eligibility

Inclusion Criteria:

  1. Age 18-45.
  2. RPOC identified on ultrasound after medical abortion, defined as endometrial thickness \>10 mm with Doppler flow into the uterine cavity.
  3. Hemodynamically stable women with bleeding comparable to menstrual flow, without fever.

Exclusion Criteria:

  1. Hemodynamic instability, excessive bleeding, or fever.
  2. Endometrial thickness \>40 mm.
  3. Endometrial thickness \<10 mm without Doppler flow into the cavity.
  4. Presence of a gestational sac within the uterine cavity.
  5. Women who received two doses of misoprostol before evaluation.

Study details
    Retained Product of Conception After First Trimester Medical Abortion

NCT07534982

Yael Yagur

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.